Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4

Chemical Research in Toxicology

Volumn 14, Issue 12, 2001, Pages 1596-1603

  Wang, E J ^a   Lew, K ^a   Barecki, M ^a   Casciano, C N ^a   Clement, R P ^a   Johnson, W W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOL; AZITHROMYCIN; CARVEDILOL; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A4 INHIBITOR; DEXTROMETHORPHAN; DICLOFENAC; EMETINE; ENZYME INHIBITOR; FLUPHENAZINE; GALLOPAMIL; GLYCOPROTEIN P; ITRACONAZOLE; LIDOCAINE; NICARDIPINE; NOBILETIN; NORVERAPAMIL; PARACETAMOL; PRAVASTATIN; RESERPINE; SIMVASTATIN; TERFENADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINOMYCIN; VERAPAMIL;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG DETERMINATION; DRUG DISPOSITION; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; INTESTINE CELL; LIVER; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN BINDING; TISSUE DISTRIBUTION;

3T3 CELLS; ANIMALS; BINDING SITES; CELL SURVIVAL; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; MICE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MOLECULAR STRUCTURE; P-GLYCOPROTEIN; SUBSTRATE SPECIFICITY;

ANIMALIA;

EID: 0035666034     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx010125x     Document Type: Article

References (59)

1. Biochemistry of multidrug resistance mediated by the multidrug transporter
2. P-glycoprotein and multidrug resistance
3. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
4. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
5. Human cytochrome P-450 enzymes
6. Cytochrome P-450 3A4: Regulation and role in drug metabolism
7. CYP3A gene expression in human gut epithelium
8. Multiple-drug resistance in human cancer
9. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and cancer chemotherapy
10. Modulators and substrates of P-glycoprotein an cytochrome P450 3A coordinately up-regulate these protein in human colon carcinomas
11. Expression of a multidrug-resistance gene in human tumors and tissues
12. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues
13. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions
14. Pharmacological considerations in the modulation of multidrug resistance
15. Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells
16. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans
17. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
18. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice
19. Role of Intestinal P-glycoprotein in interpatient variation in the oral bioavailability of cyclosporine
20. Ketoconazole effectively reverses multidrug resistance in highly resistant KB Cells
21. ShortOLINIT-term effect of medication on CYP3A4 and P-glycoprotein expression in human intestinal mucosa
22. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein
23. Two transport binding sites of p-glycoprotein are unequal yet contingent: Initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependency
24. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450
25. Cooperativity in the inhibition of P-glycoproteinmediated daunorubicin transport: Evidence for half-of-the-sites reactivity
26. Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis
27. Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein
28. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal
29. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein
30. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein
31. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein: The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes
32. Oxidation of nonionic detergents by cytochrome P-450 enzymes
33. Insights into the structure and substrate interactions of the P-glycoprotein multidrug transporter from spectroscopic studies
34. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells
35. Is the multidrug transporter a flippase?
36. Fluorescent cellular indicators are extruded by the multidrug resistance protein
37. Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein
38. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane
39. Structure-activity relationships of multidrug resistance reversers
40. Competitive, noncompetitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity
41. Reversal of multidrug resistance by bis (phenylalkyl) amines and structurally related compounds
42. Quantitative structure-activity relationship of multidrug resistance reversal agents
43. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance
44. Pharmacology of drugs that alter multidrug resistance in cancer
45. A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance
46. A general pattern for substrate recognition by P-glycoprotein
47. The importance of a nitrogen atom in modulators of multidrug resistance
48. Cooperativity in oxidations catalyzed by cytochrome P450 3A4
49. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates
50. The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4
51. Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes
52. Transport of polypeptide ionophores into proteoliposomes reconstituted with rat liver P-glycoprotein
53. The role of passive transbilayer drug movement in multidrug resistance and its modulation
54. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites
55. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analogue
56. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analogue of vinblastine
57. Aureobasidins: Structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter
58. Unique molecular conformation of aureobasidin A, a highly amide N-methylated cyclic depsipeptide with potent antifungal activity: X-ray crystal structure and molecular modeling studies
59. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors